ArticleFrontiers in cell and developmental biology2021
Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Non-coding RNAs (ncRNAs)-mediated high expression of Ras-related C3 botulinum toxin substrate 1 (RAC1) correlates with poor prognosis and tumor immune infiltration of liver hepatocellular carcinoma.Translational cancer research · 2026Article
- Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions.Frontiers in oncology · 2026Review
- Construction of a pathomics model for predicting mRNAsi in lung adenocarcinoma and exploration of biological mechanism.Heliyon · 2024Article
- Development of an immunogenic cell death-related lncRNAs signature for prognostic risk assessment in gastric cancer.Translational cancer research · 2024Article
- A novel model based on protein post-translational modifications comprising the immune landscape and prediction of colorectal cancer prognosis.Journal of gastrointestinal oncology · 2024Article
- Identification of age- and immune-related gene signatures for clinical outcome prediction in lung adenocarcinoma.Cancer medicine · 2023Article
- Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.Frontiers in immunology · 2023Article
- An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.BMC cancer · 2022Article
- Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.Frontiers in immunology · 2022Article
- A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.Frontiers in immunology · 2022Article
- mRNAsi-related metabolic risk score model identifies poor prognosis, immunoevasive contexture, and low chemotherapy response in colorectal cancer patients through machine learning.Frontiers in immunology · 2022Article
- Cancer stemness-associated LINC02475 serves as a novel biomarker for diagnosis and prognosis prediction of hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Development and Optimization of a Prognostic Model Associated with Stemness Genes in Hepatocellular Carcinoma.BioMed research international · 2022Article
- Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance.Frontiers in oncology · 2022Article
- Development and Validation of a Pyroptosis-Related Long Non-coding RNA Signature for Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.